. 2019 Nov 22;18(4):519–531. doi: 10.1007/s40258-019-00534-y

Table 4.

Incremental analysis between the two best overall vaccination strategies

Strategy	Accumulated funding in vaccination^a/years	Accumulated QALY gains	Incremental funding in vaccination^a/QALY gained
Most effective non-dominated strategies (Adj TIV 65 years+, Adj TIV 50–64 years+ QIV 18–49 years+)	$570,000,000^a × 9 = $5,130,000,000	189,956
Next best alternative (Recom QIV 65 years+, QIV 50–64 years, QIV 18–49 years)	$430,000,000^a × 9 = $3,870,000,000	183,456
Difference	$1,260,000,000	6499	$193,869

Adj adjuvanted, Recom recombinant, QIV quadrivalent influenza vaccine, TIV trivalent influenza vaccine, QALY quality-adjusted life year

^aExcludes incremental savings in disease management costs induced by most effective non-dominated strategies compared to the next best alternative